Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Haleon PLC ( (GB:HLN) ).
Haleon PLC announced the purchase of 1,600,000 ordinary shares for cancellation as part of its ongoing share buyback program. This transaction, which took place on August 15, 2025, is part of the second tranche of the program and reflects the company’s commitment to enhancing shareholder value. Following this purchase, the company’s registered share capital stands at 8,973,306,495 ordinary shares, with 8,969,426,290 shares carrying voting rights, which may impact shareholder notifications under the FCA’s rules.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £350.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Neutral.
Haleon PLC’s overall stock score is driven by strong financial performance and strategic corporate actions like share buybacks. However, technical analysis indicates bearish trends, and valuation metrics suggest moderate attractiveness. Earnings call insights reveal both opportunities and challenges, particularly in North America.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a portfolio that includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its renowned brands include Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 21,833,070
Technical Sentiment Signal: Hold
Current Market Cap: £31.97B
Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.